龐貝氏症市場按產品類型、患者類型、治療方法和分銷管道分類－2025-2032 年全球預測

預計到 2032 年龐貝氏症市場規模將成長至 24.9 億美元，複合年成長率為 5.78%。

闡述龐貝氏症的臨床現況、診斷進展以及相關人員對治療途徑和策略規劃的期望

龐貝氏症是進行性溶小體貯積症，由酸性α-Glucosidase酶缺乏引起，導致骨骼肌和心肌中糖原積聚，並表現出一系列臨床表現，從兒童期快速進展到較為緩慢的晚髮型表現型。在過去的二十年中，酵素替代療法徹底改變了臨床治療，改變了診斷和治療模式，並為長期多學科治療帶來了新的期望。新生兒篩檢、基因檢測以及對基因型-表現型相關性的深入了解等進展，使得更早發現和風險分層成為可能，而支持性治療的不斷改進也延長了許多患者的生存期並改善了功能恢復。

因此，臨床、監管、支付和生產相關人員必須適應這樣的情況：價值評估由治療效果、安全性、給藥負擔和長期療效驅動。本導言將向讀者介紹龐貝氏症的主要臨床特徵、目前的治療套件包以及影響治療可及性的系統性壓力。它為理解治療方法選擇、通路和政策變化將如何影響患者、醫療保健提供者和商業策略奠定了基礎。

此外，新型治療方法與現有酵素替代療法之間的相互作用需要綜合規劃。臨床開發團隊必須考慮不斷變化的治療標準，支付者需要可靠的真實世界證據來做出核保決策，製造商必須確保供應可靠性和成本控制。因此，本節將重點介紹龐貝氏症的臨床現狀、新興診斷趨勢以及相關人員的期望，這些因素決定了當代龐貝氏症的決策，從而構成本報告後續分析的框架。

探索科學進步、擴大新生兒篩檢、監管調整和付款人期望如何重塑治療策略和市場動態

科學創新、監管調整和護理標準的不斷演變，正在改變龐貝病的治療和商業性格局。基因療法和新一代療法正從概念走向臨床應用，促使臨床醫生和支付方重新評估長期治療流程。同時，新生兒篩檢的改進正在擴大早期發現，並增加了對及時治療性介入和多學科護理協調的需求。這些臨床進展，加上製造平台的改進，包括生技藥品的製程最佳化和對低溫運輸完整性的關注，正在影響區域供應的可靠性和成本結構。

同時，法律規範也在不斷發展，力求在嚴格的核准後證據要求與加速核准流程之間取得平衡。這些監管變革不僅促進了患者更早獲得藥物，也重新聚焦於長期療效和安全性監測，要求製造商投資於註冊和真實世界證據計畫。付款方環境也已做出調整，整合了基於療效的契約，並對高成本療法實施了更嚴格的使用控制。因此，商業化策略如今需要將臨床價值提案與對付款方和醫療保健系統至關重要的可衡量療效緊密結合。

綜上所述，這些轉變將重塑競爭優勢：那些展現出強大臨床效用、確保可靠生產和分銷、並與醫療保健系統有效合作以產生縱向數據的公司，將在不斷變化的環境中佔據最佳地位。這將對必須吸收新的診斷和治療方法方案的臨床醫生，以及越來越期望將早期檢測與持續疾病管理相結合的護理模式的患者和看護者產生連鎖反應。

評估 2025 年不斷變化的關稅和貿易動態將如何影響生物製藥供應鏈、採購壓力和戰略要務

影響供應鏈和進口成本的政策變化和貿易措施，對依賴複雜生物製藥生產和全球分銷的罕見疾病治療具有重大影響。隨著相關人員評估累積貿易措施將如何影響成本結構、採購計畫和策略採購決策，2025年的關稅發展趨勢將日益受到關注。由於許多生物製藥成品需要跨境運輸的專用組件、一次性材料和原料藥成分，上游環節的關稅和行政負擔的增加可能會波及到製造和分銷環節，從而推高商品成本並使庫存規劃複雜化。

因此，製造商可以透過重新設計供應鏈來應對，優先考慮本地生產，加強與合約開發和製造外包的合約關係，並加快本地灌裝能力建設，以減少進口關稅和邊境延誤的風險。這些調整措施可以提高韌性，但也需要前置作業時間和資本投資，進而影響產品生命週期規劃。對於醫療保健提供者和付款人而言，貿易相關的成本壓力可能表現為更嚴格的處方談判，以及對供應指標更穩定的治療方法的偏好。同時，監管機構和採購組織可能會加強對供應來源和可追溯性的審查，從而增加合規和文件記錄的營運障礙。

重要的是，雖然關稅會增加直接交易成本，但其累積影響會受到合約條款、現有賠償條款和製造商定價策略的影響。因此，相關人員應專注於基於情境的風險評估，量化整個製造價值鏈的風險敞口，並評估策略選擇，例如供應重新分配、策略性庫存持有和選擇性在岸外包。透過主動調整商業模式和合約以適應預期的供應意外情況，企業可以減輕下游中斷的影響，並維持患者獲得關鍵治療方法的管道。

確定產品類型、患者表現型、給藥順序和通路如何交叉以確定臨床路徑和商業策略

細分分析揭示了不同產品、患者類型、治療方法和通路之間的差異對臨床和商業性的影響。根據產品，市場上主要由Glucosidase酶和Glucosidase酶主導，每種藥物都有不同的證據依證、製造足跡和標籤細微差別。這些差異影響臨床醫生的處方模式和付款人談判，一些機構傾向於針對特定表現型使用長期存在的藥物，而其他機構則考慮針對特定功效和耐受性特徵的新配方。根據患者類型，嬰兒期發病和晚髮型疾病需要不同的臨床方法。嬰兒期病例通常需要緊急的多學科干預，並注意心臟和呼吸功能障礙，而晚髮型病例需要長期功能監測和個體化給藥策略，從而導致不同的支持需求和後續框架。

目錄

第1章：前言

第2章調查方法

第3章執行摘要

第4章 市場概況

第5章 市場洞察

• 擴展針對骨骼肌和心臟組織中酸性α-Glucosidase表現的下一代基因替代療法
• 擴大採用由遠端醫療監控和數位依從性工具支援的家庭酵素替代輸液服務
• 加速新生兒篩檢項目，促進高風險族群早期診斷和治療
• 新興的Chaperone輔助酵素穩定方法可改善龐貝氏症患者治療性蛋白質的細胞內輸送
• 過渡到基於長期結果和醫療資源利用的真實證據的價值型報銷模式
• 開發基於 CRISPR 的研究基因編輯候選物，用於永久糾正龐貝氏症中的嬰兒 GAA 突變
• 加強生物製藥公司和病患權益團體之間的夥伴關係，共同設計臨床試驗和以病人為中心的照護途徑

第6章：2025年美國關稅的累積影響

第7章：人工智慧的累積影響，2025年

第8章 龐貝氏症市場：依產品

• Glucosidase酶α
• Glucosidaseα

9. 龐貝氏症市場（依患者類型）

• 嬰兒發病
• 緩慢起效

10. 龐貝氏症市場（治療方法）

• 每兩週輸液一次
• 每月注射

第 11 章龐貝氏症市場（依通路）

• 醫院藥房
• 零售藥局
• 專業藥房

第 12 章龐貝氏症市場（按地區）

• 美洲
  • 北美洲
  • 拉丁美洲
• 歐洲、中東和非洲
  • 歐洲
  • 中東
  • 非洲
• 亞太地區

第13章 龐貝氏症市場（按群體）

• ASEAN
• GCC
• EU
• BRICS
• G7
• NATO

第 14 章 龐貝氏症市場（依國家）

• 美國
• 加拿大
• 墨西哥
• 巴西
• 英國
• 德國
• 法國
• 俄羅斯
• 義大利
• 西班牙
• 中國
• 印度
• 日本
• 澳洲
• 韓國

第15章競爭格局

• 2024年市佔率分析
• 2024年FPNV定位矩陣
• 競爭分析
  • Sanofi SA
  • Amicus Therapeutics, Inc.
  • Shionogi Inc.
  • Maze Therapeutics
  • GeneCradle Pharmaceutical

The Pompe Disease Market is projected to grow by USD 2.49 billion at a CAGR of 5.78% by 2032.

Contextualizing Pompe disease clinical realities, diagnostic advances, and stakeholder expectations that shape treatment access and strategic planning

Pompe disease is a progressive lysosomal storage disorder caused by deficiency of the enzyme acid alpha-glucosidase, which leads to glycogen accumulation in skeletal and cardiac muscle, producing a spectrum of clinical presentations from rapidly progressive infantile onset to more indolent late onset phenotypes. Over the past two decades, enzyme replacement therapy has transformed clinical management, shifting the diagnostic and care paradigms and creating new expectations for long-term multidisciplinary management. Advances in newborn screening, genetic diagnostics, and a deeper understanding of genotype-phenotype correlations now enable earlier detection and risk stratification, while iterative improvements in supportive care have extended survival and functional outcomes for many patients.

Consequently, stakeholders across clinical, regulatory, payer, and manufacturing domains must adapt to a landscape where treatment efficacy, safety, administration burden, and long-term outcomes drive value assessments. This introduction orients readers to the critical clinical features of Pompe disease, the current therapeutic toolkit, and the systemic pressures shaping treatment access. It provides a foundation for understanding how therapeutic choices, distribution pathways, and policy shifts will affect patients, providers, and commercial strategies in the near term.

In addition, the interplay between novel modalities and established enzyme replacement therapies necessitates integrated planning: clinical development teams must account for changing standards of care, payers require robust real-world evidence to inform coverage decisions, and manufacturers must ensure supply reliability and cost control. This section therefore frames the report's subsequent analyses by highlighting the clinical realities, emergent diagnostic trends, and stakeholder expectations that define contemporary decision-making in Pompe disease.

Exploring how scientific advances, newborn screening expansion, regulatory adaptation, and payer expectations are reshaping treatment strategies and market dynamics

The therapeutic and commercial landscape for Pompe disease has undergone transformative shifts driven by scientific innovation, regulatory adaptation, and evolving standards of care. Gene therapy and next-generation approaches have moved from conceptual stages into clinical execution, prompting clinicians and payers to reassess long-term treatment algorithms. Meanwhile, improvements in newborn screening have expanded early detection, which in turn increases demand for timely therapeutic intervention and coordination of multidisciplinary care. These clinical advances are accompanied by refinements in manufacturing platforms, including process optimization for biologics and greater emphasis on cold chain integrity, which together influence the reliability and cost structure of supply across regions.

Simultaneously, regulatory frameworks have evolved to balance accelerated pathways with rigorous post-approval evidence requirements. This regulatory evolution permits earlier patient access while placing renewed focus on long-term efficacy and safety monitoring, thereby requiring manufacturers to invest in registries and real-world evidence programs. Payer landscapes have adapted by integrating outcomes-based contracting and more stringent utilization management for high-cost therapies. As a result, commercialization strategies now demand closer alignment between clinical value propositions and measurable outcomes that matter to payers and health systems.

Taken together, these shifts reframe competitive advantage: companies that demonstrate robust clinical benefit across phenotypes, secure reliable manufacturing and distribution, and partner effectively with health systems to generate longitudinal data will be best positioned to navigate the changing environment. The ripple effects extend to clinicians, who must assimilate new diagnostic and therapeutic options, and to patients and caregivers, who increasingly expect care models that coordinate early detection with sustained disease management.

Assessing how evolving tariff and trade dynamics in 2025 create supply chain exposure, procurement pressure, and strategic imperatives for biologic therapies

Policy changes and trade measures that affect supply chains and import costs have important implications for rare disease therapies that rely on complex biologic manufacturing and global distribution. In 2025, attention to tariff dynamics has intensified as stakeholders evaluate how cumulative trade actions can influence cost structures, procurement timelines, and strategic sourcing decisions. Many finished biologic therapies require specialized components, single-use materials, and active pharmaceutical ingredients that cross multiple borders, so any incremental duty or administrative burden applied upstream can propagate through manufacturing and distribution, increasing cost of goods and complicating inventory planning.

Consequently, manufacturers may respond by redesigning supply chains to prioritize regionalized production, strengthening contractual relationships with contract development and manufacturing organizations, or accelerating localized fill-and-finish capabilities to mitigate exposure to import duties and border delays. These adaptations can enhance resilience but also require lead time and capital investment, with implications for product lifecycle planning. For healthcare providers and payers, trade-related cost pressures may manifest as tighter formulary negotiations or a preference for therapies with more stable supply metrics. At the same time, regulatory agencies and procurement bodies may intensify scrutiny of origin-of-supply and traceability, which raises the operational bar for compliance and documentation.

Importantly, while tariffs can increase direct transactional costs, their cumulative impact is mediated by contractual terms, existing indemnities, and manufacturer pricing strategies. Therefore, stakeholders should focus on scenario-based risk assessments that quantify exposure across the manufacturing value chain and evaluate strategic options such as supply reallocation, strategic stockholding, and selective onshoring. By proactively aligning commercial models and contracting with anticipated supply contingencies, organizations can reduce downstream disruptions and preserve patient access to critical therapies.

Illuminating how product type, patient phenotype, dosing cadence, and distribution routes intersect to determine clinical pathways and commercial strategies

Segmentation analysis reveals differentiated clinical and commercial implications across product, patient type, treatment regimen, and distribution channel. Based on Product, the marketplace centers on alglucosidase alfa and avalglucosidase alfa, each with distinct evidence bases, manufacturing footprints, and label nuances; these differences influence clinician prescribing patterns and payer negotiations, with some providers favoring long-established agents for certain phenotypes while others consider newer formulations for specific efficacy or tolerability profiles. Based on Patient Type, the clinical approach diverges between Infantile Onset and Late Onset populations: infantile onset cases typically require urgent, multidisciplinary intervention with attention to cardiac and respiratory compromise, while late onset patients demand long-term functional monitoring and individualized dosing strategies, creating distinct support needs and follow-up frameworks.

Based on Treatment Regimen, infusion frequency differences such as biweekly infusion and monthly infusion shape patient adherence, infusion center throughput, and home infusion feasibility; more frequent regimens can increase healthcare utilization and caregiver burden but may offer different pharmacokinetic or symptomatic benefits, whereas monthly approaches can reduce administration burden and facilitate outpatient management. Based on Distribution Channel, access pathways through hospital pharmacy, retail pharmacy, and specialty pharmacy create divergent logistics and reimbursement environments: hospital pharmacies are often integrated with infusion services and can manage complex administration, retail pharmacies may support outpatient dispensing for selected formulations, and specialty pharmacies add value through case management, prior authorization support, and coordination of home infusion services. Together, these segmentation lenses underscore that clinical value, operational feasibility, and payer acceptance are interdependent, and that effective commercialization requires tailoring evidence generation and service models to the specific constellation of product attributes, patient needs, regimen logistics, and distribution capabilities.

Hence, strategic planning should align clinical trials, health economic dossiers, and service offerings with the segmentation realities described above so that therapeutic positioning resonates with clinicians, patients, and payers across distinct use cases.

Comparing how diagnostic capacity, reimbursement models, and manufacturing footprints across major global regions shape access pathways and commercialization approaches

Regional dynamics for Pompe disease reflect heterogeneity in diagnostic infrastructure, reimbursement mechanisms, and manufacturing presence across major global blocs. In the Americas, robust newborn screening programs in some jurisdictions, coupled with established tertiary care networks, facilitate earlier diagnosis and coordinated infusion services, yet payer fragmentation and variable reimbursement pathways require manufacturers to navigate complex market access strategies and to demonstrate durable benefit across multiple healthcare models. In Europe, Middle East & Africa, regulatory harmonization across larger European markets contrasts with disparate capabilities in the Middle East and Africa where access gaps persist; as a result, market entry strategies must be regionally calibrated, with emphasis on regulatory alignment, partnerships with regional centers of excellence, and investments in capacity building where diagnostic reach is limited.

In the Asia-Pacific region, expanding genomic screening programs and growing experience with biologic therapies coexist with variable procurement practices and differing levels of local manufacturing capacity. Countries with established biomanufacturing and strong public health infrastructures have the potential to adopt advanced therapies faster, while others may prioritize cost-containment and seek negotiated pricing or risk-sharing arrangements. Across all regions, differences in infusion infrastructure, patient support ecosystems, and payer expectations mean that a one-size-fits-all approach will underperform. Therefore, regional strategies should combine evidence generation tailored to local clinical priorities, flexible pricing and contracting models, and distribution partnerships that reflect each region's logistical realities, so as to optimize patient access and commercial sustainability.

Understanding how established manufacturers, new entrants, and service partnerships compete through clinical evidence, manufacturing resilience, and patient support programs

Competitive dynamics are defined by established enzyme replacement therapy providers, newer entrants offering enhanced formulations, and a growing emphasis on integrated service delivery. Legacy manufacturers with long-term clinical data and established production networks hold credibility with clinicians and payers, while newer entrants can differentiate through improved infusion schedules, better tolerability profiles, or novel delivery modalities. Partnerships between originators and specialty pharmacy networks, contract manufacturers, or regional distributors are increasingly central to ensuring reliable supply and effective patient support, and these arrangements often determine the practical accessibility of treatments in routine care.

Moreover, competitive positioning is influenced by investment in real-world evidence and post-marketing studies, which inform guideline updates and payer coverage decisions. Companies that commit to longitudinal registries and transparent outcomes reporting strengthen their negotiating posture with health systems and can more readily engage in value-based contracting. Additionally, manufacturing resilience-evidenced by multiple production sites, validated alternative suppliers for critical raw materials, and demonstrated cold chain robustness-has become a differentiator in customer and payer discussions. The interplay between clinical differentiation and operational excellence therefore governs competitive advantage, with successful players aligning clinical development, evidence generation, and supply-chain investments to reduce friction for prescribers and to sustain patient access.

Actionable steps for leaders to align evidence generation, supply resilience, payer engagement, and service delivery to secure access and commercial sustainability

Industry leaders should prioritize an integrated approach that aligns clinical value, supply resilience, and payer engagement to preserve access and support sustainable adoption. First, invest strategically in longitudinal evidence programs that capture functional outcomes and real-world safety across infantile and late onset populations; these data underpin reimbursement discussions and inform clinical guideline updates. Next, strengthen supply chain resilience by diversifying sources for critical raw materials, evaluating regional manufacturing capabilities, and implementing contingency stock strategies to reduce exposure to cross-border disruptions and administrative trade changes.

Simultaneously, companies should design flexible service models that accommodate both biweekly infusion and monthly infusion regimens and that coordinate with hospital pharmacy, retail pharmacy, and specialty pharmacy partners to optimize patient experience and reduce administrative friction. Engage early with payers to explore outcomes-based contracting and to align on endpoints that reflect meaningful clinical benefit, including metrics that capture function, respiratory outcomes, and quality of life. Finally, foster collaborative relationships with clinical networks and patient advocacy groups to support education, adherence, and newborn screening uptake, recognizing that improved early detection combined with robust follow-up care materially improves outcomes. By synthesizing these elements-evidence, manufacturing, distribution, and stakeholder engagement-industry leaders can strengthen access pathways and ensure their portfolios meet both clinical needs and payer imperatives.

Describing the methodological framework that integrates clinician interviews, literature review, regulatory analysis, and scenario testing to ensure robust strategic insights

The research underpinning this executive summary combines a multi-source approach designed to triangulate clinical, regulatory, and commercial insights. Primary research included structured interviews with clinicians specializing in neuromuscular disorders, pharmacy directors responsible for infusion services, supply-chain managers within biologics manufacturing, and market access professionals with payer experience. These perspectives were complemented by a systematic review of peer-reviewed literature, regulatory guidance documents, clinical trial registries, and publicly available policy statements to ground conclusions in documented evidence and to capture evolving standards of care.

Analytical methods included thematic synthesis of qualitative interviews, cross-validation of regulatory and clinical milestones against publicly available filings, and scenario-based stress testing for supply chain and reimbursement contingencies. Quality control measures comprised peer review of key interpretations by domain experts, consistency checks across data sources, and sensitivity analysis where assumptions could materially affect strategic recommendations. Limitations are acknowledged: the research emphasizes published and stakeholder-reported evidence and does not include proprietary commercial data from competing organizations. Nevertheless, the methodology ensures that findings reflect a robust synthesis of clinical practice, regulatory context, and operational considerations relevant to stakeholders across the Pompe disease ecosystem.

Summarizing the strategic imperative to integrate clinical innovation, evidence generation, and operational resilience to enhance access and long-term outcomes

In conclusion, the Pompe disease landscape is defined by meaningful clinical progress, shifting diagnostic practices, and complex commercial dynamics that together require integrated strategic responses. Advances in newborn screening and evolving therapeutic options have raised expectations for early intervention and improved long-term outcomes, while regulatory and payer environments increasingly demand demonstrable real-world benefit. At the same time, trade and supply-chain considerations introduce operational risks that necessitate proactive mitigation through diversified manufacturing and regionalization strategies.

Therefore, stakeholders should adopt a holistic approach: align clinical development and evidence generation with the practicalities of administration and distribution; engage payers early around endpoints that matter to patients and health systems; and reinforce operational capabilities to ensure continuity of supply. When executed coherently, these measures will enhance patient access, improve clinical outcomes, and support sustainable therapeutic adoption across healthcare systems. This synthesis provides a strategic roadmap for decision-makers who must balance clinical innovation with pragmatic considerations of access, cost, and operational feasibility.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Expansion of next generation gene replacement therapies targeting acid alpha glucosidase expression in skeletal muscle and cardiac tissue
• 5.2. Growing adoption of home-based enzyme replacement infusion services supported by telehealth monitoring and digital adherence tools
• 5.3. Accelerating newborn screening programs to facilitate early Pompe disease diagnosis and treatment initiation in high risk populations
• 5.4. Emergence of chaperone assisted enzyme stabilization approaches to improve intracellular delivery of therapeutic proteins in Pompe patients
• 5.5. Shift toward value based reimbursement models driven by real world evidence of long term outcomes and healthcare resource utilization
• 5.6. Development of investigational CRISPR based gene editing candidates aimed at durable correction of GAA gene mutations for infantile form Pompe disease
• 5.7. Increasing partnerships between biopharma and patient advocacy groups to co design clinical trials and patient centric care pathways

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Pompe Disease Market, by Product

• 8.1. Alglucosidase Alfa
• 8.2. Avalglucosidase Alfa

9. Pompe Disease Market, by Patient Type

• 9.1. Infantile Onset
• 9.2. Late Onset

10. Pompe Disease Market, by Treatment Regimen

• 10.1. Biweekly Infusion
• 10.2. Monthly Infusion

11. Pompe Disease Market, by Distribution Channel

• 11.1. Hospital Pharmacy
• 11.2. Retail Pharmacy
• 11.3. Specialty Pharmacy

12. Pompe Disease Market, by Region

• 12.1. Americas
  • 12.1.1. North America
  • 12.1.2. Latin America
• 12.2. Europe, Middle East & Africa
  • 12.2.1. Europe
  • 12.2.2. Middle East
  • 12.2.3. Africa
• 12.3. Asia-Pacific

13. Pompe Disease Market, by Group

• 13.1. ASEAN
• 13.2. GCC
• 13.3. European Union
• 13.4. BRICS
• 13.5. G7
• 13.6. NATO

14. Pompe Disease Market, by Country

• 14.1. United States
• 14.2. Canada
• 14.3. Mexico
• 14.4. Brazil
• 14.5. United Kingdom
• 14.6. Germany
• 14.7. France
• 14.8. Russia
• 14.9. Italy
• 14.10. Spain
• 14.11. China
• 14.12. India
• 14.13. Japan
• 14.14. Australia
• 14.15. South Korea

15. Competitive Landscape

• 15.1. Market Share Analysis, 2024
• 15.2. FPNV Positioning Matrix, 2024
• 15.3. Competitive Analysis
  • 15.3.1. Sanofi S.A.
  • 15.3.2. Amicus Therapeutics, Inc.
  • 15.3.3. Shionogi Inc.
  • 15.3.4. Maze Therapeutics
  • 15.3.5. GeneCradle Pharmaceutical

LIST OF FIGURES

• FIGURE 1. GLOBAL POMPE DISEASE MARKET SIZE, 2018-2032 (USD MILLION)
• FIGURE 2. GLOBAL POMPE DISEASE MARKET SIZE, BY PRODUCT, 2024 VS 2032 (%)
• FIGURE 3. GLOBAL POMPE DISEASE MARKET SIZE, BY PRODUCT, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 4. GLOBAL POMPE DISEASE MARKET SIZE, BY PATIENT TYPE, 2024 VS 2032 (%)
• FIGURE 5. GLOBAL POMPE DISEASE MARKET SIZE, BY PATIENT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 6. GLOBAL POMPE DISEASE MARKET SIZE, BY TREATMENT REGIMEN, 2024 VS 2032 (%)
• FIGURE 7. GLOBAL POMPE DISEASE MARKET SIZE, BY TREATMENT REGIMEN, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 8. GLOBAL POMPE DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
• FIGURE 9. GLOBAL POMPE DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 10. GLOBAL POMPE DISEASE MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 11. AMERICAS POMPE DISEASE MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 12. NORTH AMERICA POMPE DISEASE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 13. LATIN AMERICA POMPE DISEASE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 14. EUROPE, MIDDLE EAST & AFRICA POMPE DISEASE MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 15. EUROPE POMPE DISEASE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 16. MIDDLE EAST POMPE DISEASE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 17. AFRICA POMPE DISEASE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 18. ASIA-PACIFIC POMPE DISEASE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 19. GLOBAL POMPE DISEASE MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 20. ASEAN POMPE DISEASE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 21. GCC POMPE DISEASE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 22. EUROPEAN UNION POMPE DISEASE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 23. BRICS POMPE DISEASE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 24. G7 POMPE DISEASE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 25. NATO POMPE DISEASE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 26. GLOBAL POMPE DISEASE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 27. POMPE DISEASE MARKET SHARE, BY KEY PLAYER, 2024
• FIGURE 28. POMPE DISEASE MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

• TABLE 1. POMPE DISEASE MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
• TABLE 3. GLOBAL POMPE DISEASE MARKET SIZE, 2018-2024 (USD MILLION)
• TABLE 4. GLOBAL POMPE DISEASE MARKET SIZE, 2025-2032 (USD MILLION)
• TABLE 5. GLOBAL POMPE DISEASE MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
• TABLE 6. GLOBAL POMPE DISEASE MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
• TABLE 7. GLOBAL POMPE DISEASE MARKET SIZE, BY ALGLUCOSIDASE ALFA, BY REGION, 2018-2024 (USD MILLION)
• TABLE 8. GLOBAL POMPE DISEASE MARKET SIZE, BY ALGLUCOSIDASE ALFA, BY REGION, 2025-2032 (USD MILLION)
• TABLE 9. GLOBAL POMPE DISEASE MARKET SIZE, BY ALGLUCOSIDASE ALFA, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 10. GLOBAL POMPE DISEASE MARKET SIZE, BY ALGLUCOSIDASE ALFA, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 11. GLOBAL POMPE DISEASE MARKET SIZE, BY ALGLUCOSIDASE ALFA, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 12. GLOBAL POMPE DISEASE MARKET SIZE, BY ALGLUCOSIDASE ALFA, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 13. GLOBAL POMPE DISEASE MARKET SIZE, BY AVALGLUCOSIDASE ALFA, BY REGION, 2018-2024 (USD MILLION)
• TABLE 14. GLOBAL POMPE DISEASE MARKET SIZE, BY AVALGLUCOSIDASE ALFA, BY REGION, 2025-2032 (USD MILLION)
• TABLE 15. GLOBAL POMPE DISEASE MARKET SIZE, BY AVALGLUCOSIDASE ALFA, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 16. GLOBAL POMPE DISEASE MARKET SIZE, BY AVALGLUCOSIDASE ALFA, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 17. GLOBAL POMPE DISEASE MARKET SIZE, BY AVALGLUCOSIDASE ALFA, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 18. GLOBAL POMPE DISEASE MARKET SIZE, BY AVALGLUCOSIDASE ALFA, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 19. GLOBAL POMPE DISEASE MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
• TABLE 20. GLOBAL POMPE DISEASE MARKET SIZE, BY PATIENT TYPE, 2025-2032 (USD MILLION)
• TABLE 21. GLOBAL POMPE DISEASE MARKET SIZE, BY INFANTILE ONSET, BY REGION, 2018-2024 (USD MILLION)
• TABLE 22. GLOBAL POMPE DISEASE MARKET SIZE, BY INFANTILE ONSET, BY REGION, 2025-2032 (USD MILLION)
• TABLE 23. GLOBAL POMPE DISEASE MARKET SIZE, BY INFANTILE ONSET, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 24. GLOBAL POMPE DISEASE MARKET SIZE, BY INFANTILE ONSET, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 25. GLOBAL POMPE DISEASE MARKET SIZE, BY INFANTILE ONSET, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 26. GLOBAL POMPE DISEASE MARKET SIZE, BY INFANTILE ONSET, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 27. GLOBAL POMPE DISEASE MARKET SIZE, BY LATE ONSET, BY REGION, 2018-2024 (USD MILLION)
• TABLE 28. GLOBAL POMPE DISEASE MARKET SIZE, BY LATE ONSET, BY REGION, 2025-2032 (USD MILLION)
• TABLE 29. GLOBAL POMPE DISEASE MARKET SIZE, BY LATE ONSET, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 30. GLOBAL POMPE DISEASE MARKET SIZE, BY LATE ONSET, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 31. GLOBAL POMPE DISEASE MARKET SIZE, BY LATE ONSET, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 32. GLOBAL POMPE DISEASE MARKET SIZE, BY LATE ONSET, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 33. GLOBAL POMPE DISEASE MARKET SIZE, BY TREATMENT REGIMEN, 2018-2024 (USD MILLION)
• TABLE 34. GLOBAL POMPE DISEASE MARKET SIZE, BY TREATMENT REGIMEN, 2025-2032 (USD MILLION)
• TABLE 35. GLOBAL POMPE DISEASE MARKET SIZE, BY BIWEEKLY INFUSION, BY REGION, 2018-2024 (USD MILLION)
• TABLE 36. GLOBAL POMPE DISEASE MARKET SIZE, BY BIWEEKLY INFUSION, BY REGION, 2025-2032 (USD MILLION)
• TABLE 37. GLOBAL POMPE DISEASE MARKET SIZE, BY BIWEEKLY INFUSION, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 38. GLOBAL POMPE DISEASE MARKET SIZE, BY BIWEEKLY INFUSION, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 39. GLOBAL POMPE DISEASE MARKET SIZE, BY BIWEEKLY INFUSION, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 40. GLOBAL POMPE DISEASE MARKET SIZE, BY BIWEEKLY INFUSION, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 41. GLOBAL POMPE DISEASE MARKET SIZE, BY MONTHLY INFUSION, BY REGION, 2018-2024 (USD MILLION)
• TABLE 42. GLOBAL POMPE DISEASE MARKET SIZE, BY MONTHLY INFUSION, BY REGION, 2025-2032 (USD MILLION)
• TABLE 43. GLOBAL POMPE DISEASE MARKET SIZE, BY MONTHLY INFUSION, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 44. GLOBAL POMPE DISEASE MARKET SIZE, BY MONTHLY INFUSION, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 45. GLOBAL POMPE DISEASE MARKET SIZE, BY MONTHLY INFUSION, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 46. GLOBAL POMPE DISEASE MARKET SIZE, BY MONTHLY INFUSION, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 47. GLOBAL POMPE DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 48. GLOBAL POMPE DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 49. GLOBAL POMPE DISEASE MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 50. GLOBAL POMPE DISEASE MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 51. GLOBAL POMPE DISEASE MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 52. GLOBAL POMPE DISEASE MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 53. GLOBAL POMPE DISEASE MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 54. GLOBAL POMPE DISEASE MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 55. GLOBAL POMPE DISEASE MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 56. GLOBAL POMPE DISEASE MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 57. GLOBAL POMPE DISEASE MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 58. GLOBAL POMPE DISEASE MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 59. GLOBAL POMPE DISEASE MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 60. GLOBAL POMPE DISEASE MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 61. GLOBAL POMPE DISEASE MARKET SIZE, BY SPECIALTY PHARMACY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 62. GLOBAL POMPE DISEASE MARKET SIZE, BY SPECIALTY PHARMACY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 63. GLOBAL POMPE DISEASE MARKET SIZE, BY SPECIALTY PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 64. GLOBAL POMPE DISEASE MARKET SIZE, BY SPECIALTY PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 65. GLOBAL POMPE DISEASE MARKET SIZE, BY SPECIALTY PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 66. GLOBAL POMPE DISEASE MARKET SIZE, BY SPECIALTY PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 67. GLOBAL POMPE DISEASE MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 68. GLOBAL POMPE DISEASE MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 69. AMERICAS POMPE DISEASE MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
• TABLE 70. AMERICAS POMPE DISEASE MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
• TABLE 71. AMERICAS POMPE DISEASE MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
• TABLE 72. AMERICAS POMPE DISEASE MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
• TABLE 73. AMERICAS POMPE DISEASE MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
• TABLE 74. AMERICAS POMPE DISEASE MARKET SIZE, BY PATIENT TYPE, 2025-2032 (USD MILLION)
• TABLE 75. AMERICAS POMPE DISEASE MARKET SIZE, BY TREATMENT REGIMEN, 2018-2024 (USD MILLION)
• TABLE 76. AMERICAS POMPE DISEASE MARKET SIZE, BY TREATMENT REGIMEN, 2025-2032 (USD MILLION)
• TABLE 77. AMERICAS POMPE DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 78. AMERICAS POMPE DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 79. NORTH AMERICA POMPE DISEASE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 80. NORTH AMERICA POMPE DISEASE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 81. NORTH AMERICA POMPE DISEASE MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
• TABLE 82. NORTH AMERICA POMPE DISEASE MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
• TABLE 83. NORTH AMERICA POMPE DISEASE MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
• TABLE 84. NORTH AMERICA POMPE DISEASE MARKET SIZE, BY PATIENT TYPE, 2025-2032 (USD MILLION)
• TABLE 85. NORTH AMERICA POMPE DISEASE MARKET SIZE, BY TREATMENT REGIMEN, 2018-2024 (USD MILLION)
• TABLE 86. NORTH AMERICA POMPE DISEASE MARKET SIZE, BY TREATMENT REGIMEN, 2025-2032 (USD MILLION)
• TABLE 87. NORTH AMERICA POMPE DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 88. NORTH AMERICA POMPE DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 89. LATIN AMERICA POMPE DISEASE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 90. LATIN AMERICA POMPE DISEASE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 91. LATIN AMERICA POMPE DISEASE MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
• TABLE 92. LATIN AMERICA POMPE DISEASE MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
• TABLE 93. LATIN AMERICA POMPE DISEASE MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
• TABLE 94. LATIN AMERICA POMPE DISEASE MARKET SIZE, BY PATIENT TYPE, 2025-2032 (USD MILLION)
• TABLE 95. LATIN AMERICA POMPE DISEASE MARKET SIZE, BY TREATMENT REGIMEN, 2018-2024 (USD MILLION)
• TABLE 96. LATIN AMERICA POMPE DISEASE MARKET SIZE, BY TREATMENT REGIMEN, 2025-2032 (USD MILLION)
• TABLE 97. LATIN AMERICA POMPE DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 98. LATIN AMERICA POMPE DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 99. EUROPE, MIDDLE EAST & AFRICA POMPE DISEASE MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
• TABLE 100. EUROPE, MIDDLE EAST & AFRICA POMPE DISEASE MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
• TABLE 101. EUROPE, MIDDLE EAST & AFRICA POMPE DISEASE MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
• TABLE 102. EUROPE, MIDDLE EAST & AFRICA POMPE DISEASE MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
• TABLE 103. EUROPE, MIDDLE EAST & AFRICA POMPE DISEASE MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
• TABLE 104. EUROPE, MIDDLE EAST & AFRICA POMPE DISEASE MARKET SIZE, BY PATIENT TYPE, 2025-2032 (USD MILLION)
• TABLE 105. EUROPE, MIDDLE EAST & AFRICA POMPE DISEASE MARKET SIZE, BY TREATMENT REGIMEN, 2018-2024 (USD MILLION)
• TABLE 106. EUROPE, MIDDLE EAST & AFRICA POMPE DISEASE MARKET SIZE, BY TREATMENT REGIMEN, 2025-2032 (USD MILLION)
• TABLE 107. EUROPE, MIDDLE EAST & AFRICA POMPE DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 108. EUROPE, MIDDLE EAST & AFRICA POMPE DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 109. EUROPE POMPE DISEASE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 110. EUROPE POMPE DISEASE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 111. EUROPE POMPE DISEASE MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
• TABLE 112. EUROPE POMPE DISEASE MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
• TABLE 113. EUROPE POMPE DISEASE MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
• TABLE 114. EUROPE POMPE DISEASE MARKET SIZE, BY PATIENT TYPE, 2025-2032 (USD MILLION)
• TABLE 115. EUROPE POMPE DISEASE MARKET SIZE, BY TREATMENT REGIMEN, 2018-2024 (USD MILLION)
• TABLE 116. EUROPE POMPE DISEASE MARKET SIZE, BY TREATMENT REGIMEN, 2025-2032 (USD MILLION)
• TABLE 117. EUROPE POMPE DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 118. EUROPE POMPE DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 119. MIDDLE EAST POMPE DISEASE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 120. MIDDLE EAST POMPE DISEASE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 121. MIDDLE EAST POMPE DISEASE MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
• TABLE 122. MIDDLE EAST POMPE DISEASE MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
• TABLE 123. MIDDLE EAST POMPE DISEASE MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
• TABLE 124. MIDDLE EAST POMPE DISEASE MARKET SIZE, BY PATIENT TYPE, 2025-2032 (USD MILLION)
• TABLE 125. MIDDLE EAST POMPE DISEASE MARKET SIZE, BY TREATMENT REGIMEN, 2018-2024 (USD MILLION)
• TABLE 126. MIDDLE EAST POMPE DISEASE MARKET SIZE, BY TREATMENT REGIMEN, 2025-2032 (USD MILLION)
• TABLE 127. MIDDLE EAST POMPE DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 128. MIDDLE EAST POMPE DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 129. AFRICA POMPE DISEASE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 130. AFRICA POMPE DISEASE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 131. AFRICA POMPE DISEASE MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
• TABLE 132. AFRICA POMPE DISEASE MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
• TABLE 133. AFRICA POMPE DISEASE MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
• TABLE 134. AFRICA POMPE DISEASE MARKET SIZE, BY PATIENT TYPE, 2025-2032 (USD MILLION)
• TABLE 135. AFRICA POMPE DISEASE MARKET SIZE, BY TREATMENT REGIMEN, 2018-2024 (USD MILLION)
• TABLE 136. AFRICA POMPE DISEASE MARKET SIZE, BY TREATMENT REGIMEN, 2025-2032 (USD MILLION)
• TABLE 137. AFRICA POMPE DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 138. AFRICA POMPE DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 139. ASIA-PACIFIC POMPE DISEASE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 140. ASIA-PACIFIC POMPE DISEASE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 141. ASIA-PACIFIC POMPE DISEASE MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
• TABLE 142. ASIA-PACIFIC POMPE DISEASE MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
• TABLE 143. ASIA-PACIFIC POMPE DISEASE MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
• TABLE 144. ASIA-PACIFIC POMPE DISEASE MARKET SIZE, BY PATIENT TYPE, 2025-2032 (USD MILLION)
• TABLE 145. ASIA-PACIFIC POMPE DISEASE MARKET SIZE, BY TREATMENT REGIMEN, 2018-2024 (USD MILLION)
• TABLE 146. ASIA-PACIFIC POMPE DISEASE MARKET SIZE, BY TREATMENT REGIMEN, 2025-2032 (USD MILLION)
• TABLE 147. ASIA-PACIFIC POMPE DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 148. ASIA-PACIFIC POMPE DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 149. GLOBAL POMPE DISEASE MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 150. GLOBAL POMPE DISEASE MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 151. ASEAN POMPE DISEASE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 152. ASEAN POMPE DISEASE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 153. ASEAN POMPE DISEASE MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
• TABLE 154. ASEAN POMPE DISEASE MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
• TABLE 155. ASEAN POMPE DISEASE MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
• TABLE 156. ASEAN POMPE DISEASE MARKET SIZE, BY PATIENT TYPE, 2025-2032 (USD MILLION)
• TABLE 157. ASEAN POMPE DISEASE MARKET SIZE, BY TREATMENT REGIMEN, 2018-2024 (USD MILLION)
• TABLE 158. ASEAN POMPE DISEASE MARKET SIZE, BY TREATMENT REGIMEN, 2025-2032 (USD MILLION)
• TABLE 159. ASEAN POMPE DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 160. ASEAN POMPE DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 161. GCC POMPE DISEASE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 162. GCC POMPE DISEASE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 163. GCC POMPE DISEASE MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
• TABLE 164. GCC POMPE DISEASE MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
• TABLE 165. GCC POMPE DISEASE MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
• TABLE 166. GCC POMPE DISEASE MARKET SIZE, BY PATIENT TYPE, 2025-2032 (USD MILLION)
• TABLE 167. GCC POMPE DISEASE MARKET SIZE, BY TREATMENT REGIMEN, 2018-2024 (USD MILLION)
• TABLE 168. GCC POMPE DISEASE MARKET SIZE, BY TREATMENT REGIMEN, 2025-2032 (USD MILLION)
• TABLE 169. GCC POMPE DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 170. GCC POMPE DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 171. EUROPEAN UNION POMPE DISEASE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 172. EUROPEAN UNION POMPE DISEASE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 173. EUROPEAN UNION POMPE DISEASE MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
• TABLE 174. EUROPEAN UNION POMPE DISEASE MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
• TABLE 175. EUROPEAN UNION POMPE DISEASE MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
• TABLE 176. EUROPEAN UNION POMPE DISEASE MARKET SIZE, BY PATIENT TYPE, 2025-2032 (USD MILLION)
• TABLE 177. EUROPEAN UNION POMPE DISEASE MARKET SIZE, BY TREATMENT REGIMEN, 2018-2024 (USD MILLION)
• TABLE 178. EUROPEAN UNION POMPE DISEASE MARKET SIZE, BY TREATMENT REGIMEN, 2025-2032 (USD MILLION)
• TABLE 179. EUROPEAN UNION POMPE DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 180. EUROPEAN UNION POMPE DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 181. BRICS POMPE DISEASE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 182. BRICS POMPE DISEASE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 183. BRICS POMPE DISEASE MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
• TABLE 184. BRICS POMPE DISEASE MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
• TABLE 185. BRICS POMPE DISEASE MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
• TABLE 186. BRICS POMPE DISEASE MARKET SIZE, BY PATIENT TYPE, 2025-2032 (USD MILLION)
• TABLE 187. BRICS POMPE DISEASE MARKET SIZE, BY TREATMENT REGIMEN, 2018-2024 (USD MILLION)
• TABLE 188. BRICS POMPE DISEASE MARKET SIZE, BY TREATMENT REGIMEN, 2025-2032 (USD MILLION)
• TABLE 189. BRICS POMPE DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 190. BRICS POMPE DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 191. G7 POMPE DISEASE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 192. G7 POMPE DISEASE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 193. G7 POMPE DISEASE MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
• TABLE 194. G7 POMPE DISEASE MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
• TABLE 195. G7 POMPE DISEASE MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
• TABLE 196. G7 POMPE DISEASE MARKET SIZE, BY PATIENT TYPE, 2025-2032 (USD MILLION)
• TABLE 197. G7 POMPE DISEASE MARKET SIZE, BY TREATMENT REGIMEN, 2018-2024 (USD MILLION)
• TABLE 198. G7 POMPE DISEASE MARKET SIZE, BY TREATMENT REGIMEN, 2025-2032 (USD MILLION)
• TABLE 199. G7 POMPE DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 200. G7 POMPE DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 201. NATO POMPE DISEASE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 202. NATO POMPE DISEASE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 203. NATO POMPE DISEASE MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
• TABLE 204. NATO POMPE DISEASE MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
• TABLE 205. NATO POMPE DISEASE MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
• TABLE 206. NATO POMPE DISEASE MARKET SIZE, BY PATIENT TYPE, 2025-2032 (USD MILLION)
• TABLE 207. NATO POMPE DISEASE MARKET SIZE, BY TREATMENT REGIMEN, 2018-2024 (USD MILLION)
• TABLE 208. NATO POMPE DISEASE MARKET SIZE, BY TREATMENT REGIMEN, 2025-2032 (USD MILLION)
• TABLE 209. NATO POMPE DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 210. NATO POMPE DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 211. GLOBAL POMPE DISEASE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 212. GLOBAL POMPE DISEASE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 213. UNITED STATES POMPE DISEASE MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
• TABLE 214. UNITED STATES POMPE DISEASE MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
• TABLE 215. UNITED STATES POMPE DISEASE MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
• TABLE 216. UNITED STATES POMPE DISEASE MARKET SIZE, BY PATIENT TYPE, 2025-2032 (USD MILLION)
• TABLE 217. UNITED STATES POMPE DISEASE MARKET SIZE, BY TREATMENT REGIMEN, 2018-2024 (USD MILLION)
• TABLE 218. UNITED STATES POMPE DISEASE MARKET SIZE, BY TREATMENT REGIMEN, 2025-2032 (USD MILLION)
• TABLE 219. UNITED STATES POMPE DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 220. UNITED STATES POMPE DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 221. CANADA POMPE DISEASE MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
• TABLE 222. CANADA POMPE DISEASE MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
• TABLE 223. CANADA POMPE DISEASE MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
• TABLE 224. CANADA POMPE DISEASE MARKET SIZE, BY PATIENT TYPE, 2025-2032 (USD MILLION)
• TABLE 225. CANADA POMPE DISEASE MARKET SIZE, BY TREATMENT REGIMEN, 2018-2024 (USD MILLION)
• TABLE 226. CANADA POMPE DISEASE MARKET SIZE, BY TREATMENT REGIMEN, 2025-2032 (USD MILLION)
• TABLE 227. CANADA POMPE DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 228. CANADA POMPE DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 229. MEXICO POMPE DISEASE MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
• TABLE 230. MEXICO POMPE DISEASE MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
• TABLE 231. MEXICO POMPE DISEASE MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
• TABLE 232. MEXICO POMPE DISEASE MARKET SIZE, BY PATIENT TYPE, 2025-2032 (USD MILLION)
• TABLE 233. MEXICO POMPE DISEASE MARKET SIZE, BY TREATMENT REGIMEN, 2018-2024 (USD MILLION)
• TABLE 234. MEXICO POMPE DISEASE MARKET SIZE, BY TREATMENT REGIMEN, 2025-2032 (USD MILLION)
• TABLE 235. MEXICO POMPE DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 236. MEXICO POMPE DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 237. BRAZIL POMPE DISEASE MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
• TABLE 238. BRAZIL POMPE DISEASE MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
• TABLE 239. BRAZIL POMPE DISEASE MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
• TABLE 240. BRAZIL POMPE DISEASE MARKET SIZE, BY PATIENT TYPE, 2025-2032 (USD MILLION)
• TABLE 241. BRAZIL POMPE DISEASE MARKET SIZE, BY TREATMENT REGIMEN, 2018-2024 (USD MILLION)
• TABLE 242. BRAZIL POMPE DISEASE MARKET SIZE, BY TREATMENT REGIMEN, 2025-2032 (USD MILLION)
• TABLE 243. BRAZIL POMPE DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 244. BRAZIL POMPE DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 245. UNITED KINGDOM POMPE DISEASE MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
• TABLE 246. UNITED KINGDOM POMPE DISEASE MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
• TABLE 247. UNITED KINGDOM POMPE DISEASE MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
• TABLE 248. UNITED KINGDOM POMPE DISEASE MARKET SIZE, BY PATIENT TYPE, 2025-2032 (USD MILLION)
• TABLE 249. UNITED KINGDOM POMPE DISEASE MARKET SIZE, BY TREATMENT REGIMEN, 2018-2024 (USD MILLION)
• TABLE 250. UNITED KINGDOM POMPE DISEASE MARKET SIZE, BY TREATMENT REGIMEN, 2025-2032 (USD MILLION)
• TABLE 251. UNITED KINGDOM POMPE DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 252. UNITED KINGDOM POMPE DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 253. GERMANY POMPE DISEASE MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
• TABLE 254. GERMANY POMPE DISEASE MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
• TABLE 255. GERMANY POMPE DISEASE MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
• TABLE 256. GERMANY POMPE DISEASE MARKET SIZE, BY PATIENT TYPE, 2025-2032 (USD MILLION)
• TABLE 257. GERMANY POMPE DISEASE MARKET SIZE, BY TREATMENT REGIMEN, 2018-2024 (USD MILLION)
• TABLE 258. GERMANY POMPE DISEASE MARKET SIZE, BY TREATMENT REGIMEN, 2025-2032 (USD MILLION)
• TABLE 259. GERMANY POMPE DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 260. GERMANY POMPE DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 261. FRANCE POMPE DISEASE MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
• TABLE 262. FRANCE POMPE DISEASE MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
• TABLE 263. FRANCE POMPE DISEASE MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
• TABLE 264. FRANCE POMPE DISEASE MARKET SIZE, BY PATIENT TYPE, 2025-2032 (USD MILLION)
• TABLE 265. FRANCE POMPE DISEASE MARKET SIZE, BY TREATMENT REGIMEN, 2018-2024 (USD MILLION)
• TABLE 266. FRANCE POMPE DISEASE MARKET SIZE, BY TREATMENT REGIMEN, 2025-2032 (USD MILLION)
• TABLE 267. FRANCE POMPE DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 268. FRANCE POMPE DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 269. RUSSIA POMPE DISEASE MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
• TABLE 270. RUSSIA POMPE DISEASE MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
• TABLE 271. RUSSIA POMPE DISEASE MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
• TABLE 272. RUSSIA POMPE DISEASE MARKET SIZE, BY PATIENT TYPE, 2025-2032 (USD MILLION)
• TABLE 273. RUSSIA POMPE DISEASE MARKET SIZE, BY TREATMENT REGIMEN, 2018-2024 (USD MILLION)
• TABLE 274. RUSSIA POMPE DISEASE MARKET SIZE, BY TREATMENT REGIMEN, 2025-2032 (USD MILLION)
• TABLE 275. RUSSIA POMPE DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 276. RUSSIA POMPE DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 277. ITALY POMPE DISEASE MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
• TABLE 278. ITALY POMPE DISEASE MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
• TABLE 279. ITALY POMPE DISEASE MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
• TABLE 280. ITALY POMPE DISEASE MARKET SIZE, BY PATIENT TYPE, 2025-2032 (USD MILLION)
• TABLE 281. ITALY POMPE DISEASE MARKET SIZE, BY TREATMENT REGIMEN, 2018-2024 (USD MILLION)
• TABLE 282. ITALY POMPE DISEASE MARKET SIZE, BY TREATMENT REGIMEN, 2025-2032 (USD MILLION)
• TABLE 283. ITALY POMPE DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 284. ITALY POMPE DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 285. SPAIN POMPE DISEASE MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
• TABLE 286. SPAIN POMPE DISEASE MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
• TABLE 287. SPAIN POMPE DISEASE MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
• TABLE 288. SPAIN POMPE DISEASE MARKET SIZE, BY PATIENT TYPE, 2025-2032 (USD MILLION)
• TABLE 289. SPAIN POMPE DISEASE MARKET SIZE, BY TREATMENT REGIMEN, 2018-2024 (USD MILLION)
• TABLE 290. SPAIN POMPE DISEASE MARKET SIZE, BY TREATMENT REGIMEN, 2025-2032 (USD MILLION)
• TABLE 291. SPAIN POMPE DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 292. SPAIN POMPE DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 293. CHINA POMPE DISEASE MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
• TABLE 294. CHINA POMPE DISEASE MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
• TABLE 295. CHINA POMPE DISEASE MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
• TABLE 296. CHINA POMPE DISEASE MARKET SIZE, BY PATIENT TYPE, 2025-2032 (USD MILLION)
• TABLE 297. CHINA POMPE DISEASE MARKET SIZE, BY TREATMENT REGIMEN, 2018-2024 (USD MILLION)
• TABLE 298. CHINA POMPE DISEASE MARKET SIZE, BY TREATMENT REGIMEN, 2025-2032 (USD MILLION)
• TABLE 299. CHINA POMPE DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 300. CHINA POMPE DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 301. INDIA POMPE DISEASE MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
• TABLE 302. INDIA POMPE DISEASE MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
• TABLE 303. INDIA POMPE DISEASE MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
• TABLE 304. INDIA POMPE DISEASE MARKET SIZE, BY PATIENT TYPE, 2025-2032 (USD MILLION)
• TABLE 305. INDIA POMPE DISEASE MARKET SIZE, BY TREATMENT REGIMEN, 2018-2024 (USD MILLION)
• TABLE 306. INDIA POMPE DISEASE MARKET SIZE, BY TREATMENT REGIMEN, 2025-2032 (USD MILLION)
• TABLE 307. INDIA POMPE DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 308. INDIA POMPE DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 309. JAPAN POMPE DISEASE MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
• TABLE 310. JAPAN POMPE DISEASE MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
• TABLE 311. JAPAN POMPE DISEASE MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
• TABLE 312. JAPAN POMPE DISEASE MARKET SIZE, BY PATIENT TYPE, 2025-2032 (USD MILLION)
• TABLE 313. JAPAN POMPE DISEASE MARKET SIZE, BY TREATMENT REGIMEN, 2018-2024 (USD MILLION)
• TABLE 314. JAPAN POMPE DISEASE MARKET SIZE, BY TREATMENT REGIMEN, 2025-2032 (USD MILLION)
• TABLE 315. JAPAN POMPE DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 316. JAPAN POMPE DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 317. AUSTRALIA POMPE DISEASE MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
• TABLE 318. AUSTRALIA POMPE DISEASE MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
• TABLE 319. AUSTRALIA POMPE DISEASE MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
• TABLE 320. AUSTRALIA POMPE DISEASE MARKET SIZE, BY PATIENT TYPE, 2025-2032 (USD MILLION)
• TABLE 321. AUSTRALIA POMPE DISEASE MARKET SIZE, BY TREATMENT REGIMEN, 2018-2024 (USD MILLION)
• TABLE 322. AUSTRALIA POMPE DISEASE MARKET SIZE, BY TREATMENT REGIMEN, 2025-2032 (USD MILLION)
• TABLE 323. AUSTRALIA POMPE DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 324. AUSTRALIA POMPE DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 325. SOUTH KOREA POMPE DISEASE MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
• TABLE 326. SOUTH KOREA POMPE DISEASE MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
• TABLE 327. SOUTH KOREA POMPE DISEASE MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
• TABLE 328. SOUTH KOREA POMPE DISEASE MARKET SIZE, BY PATIENT TYPE, 2025-2032 (USD MILLION)
• TABLE 329. SOUTH KOREA POMPE DISEASE MARKET SIZE, BY TREATMENT REGIMEN, 2018-2024 (USD MILLION)
• TABLE 330. SOUTH KOREA POMPE DISEASE MARKET SIZE, BY TREATMENT REGIMEN, 2025-2032 (USD MILLION)
• TABLE 331. SOUTH KOREA POMPE DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 332. SOUTH KOREA POMPE DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 333. POMPE DISEASE MARKET SHARE, BY KEY PLAYER, 2024
• TABLE 334. POMPE DISEASE MARKET, FPNV POSITIONING MATRIX, 2024